-
1
-
-
38949192547
-
Targeted cancer therapy: conferring specificity to cytotoxic drugs
-
Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41:98-107.
-
(2008)
Acc Chem Res.
, vol.41
, pp. 98-107
-
-
Chari, R.V.1
-
2
-
-
56449129810
-
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate
-
Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68: 9280-9290.
-
(2008)
Cancer Res.
, vol.68
, pp. 9280-9290
-
-
Lewis Phillips, G.D.1
Li, G.2
Dugger, D.L.3
-
3
-
-
77954031486
-
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer
-
Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2010;28:2698-2704.
-
(2010)
J Clin Oncol.
, vol.28
, pp. 2698-2704
-
-
Krop, I.E.1
Beeram, M.2
Modi, S.3
-
4
-
-
79952092706
-
Phase II study of the antibody drug conjugate trastuzumab-DM1 (T-DM1) for the treatment of HER2-positive breast cancer following prior HER2-directed therapy
-
Burris HA III, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 (T-DM1) for the treatment of HER2-positive breast cancer following prior HER2-directed therapy. J Clin Oncol. 2011;29: 398-405.
-
(2011)
J Clin Oncol.
, vol.29
, pp. 398-405
-
-
Burris, H.A.1
Rugo, H.S.2
Vukelja, S.J.3
-
5
-
-
79959700509
-
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
-
Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. 2011;128:347-356.
-
(2011)
Breast Cancer Res Treat.
, vol.128
, pp. 347-356
-
-
Junttila, T.T.1
Li, G.2
Parsons, K.3
Phillips, G.L.4
Sliwkowski, M.X.5
-
6
-
-
84863688392
-
A phase II study of trastuzumab emtansine (T-DM1) in patients with human epidermal growth factor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine
-
Krop I, LoRusso P, Miller KD, et al. A phase II study of trastuzumab emtansine (T-DM1) in patients with human epidermal growth factor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2012;30:3234-3241.
-
(2012)
J Clin Oncol.
, vol.30
, pp. 3234-3241
-
-
Krop, I.1
LoRusso, P.2
Miller, K.D.3
-
7
-
-
84874822884
-
A phase 2 randomized study of trastuzumab emtansine (T-DM1) versus trastuzumab docetaxel in patients with HER2-positive metastatic breast cancer
-
[in press]
-
Hurvitz SA, Dirix L, Kocsis J, et al. A phase 2 randomized study of trastuzumab emtansine (T-DM1) versus trastuzumab docetaxel in patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2013; [in press].
-
(2013)
J Clin Oncol.
-
-
Hurvitz, S.A.1
Dirix, L.2
Kocsis, J.3
-
8
-
-
84868520609
-
Trastuzumab emtansine for HER2-positive advanced breast cancer
-
Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. New Engl J Med 2012;367:1783-1791.
-
(2012)
New Engl J Med
, vol.367
, pp. 1783-1791
-
-
Verma, S.1
Miles, D.2
Gianni, L.3
-
9
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
-
(2001)
N Engl J Med.
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
-
10
-
-
80052728749
-
Four-year followup of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31
-
Perez EA, Romond EH, Suman VJ, et al. Four-year followup of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29:3366-3373.
-
(2011)
J Clin Oncol.
, vol.29
, pp. 3366-3373
-
-
Perez, E.A.1
Romond, E.H.2
Suman, V.J.3
-
11
-
-
44949253343
-
Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials
-
Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clinic Proc. 2008;83:679-686.
-
(2008)
Mayo Clinic Proc.
, vol.83
, pp. 679-686
-
-
Perez, E.A.1
Koehler, M.2
Byrne, J.3
Preston, A.J.4
Rappold, E.5
Ewer, M.S.6
-
12
-
-
84892489044
-
-
U.S,Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). International conference on harmonisation guidance for industry: E14 clinical evaluation of QT/ QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs,Published October 2005. Accessed February 15, 2012
-
U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). International conference on harmonisation guidance for industry: E14 clinical evaluation of QT/ QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. http://www.fda.gov/downloads/ RegulatoryInformation/Guidances/UCM129357.pdf. Published October 2005. Accessed February 15, 2012.
-
Department of Health and Human Services Food and Drug Administration
-
-
-
13
-
-
14544268139
-
QT prolongation through hERG K() channel blockade: current knowledge and strategies for the early prediction during drug development
-
Recanatini M, Poluzzi E, Masetti M, Cavalli A, De Ponti F. QT prolongation through hERG K() channel blockade: current knowledge and strategies for the early prediction during drug development. Med Res Rev. 2005;25:133-166.
-
(2005)
Med Res Rev.
, vol.25
, pp. 133-166
-
-
Recanatini, M.1
Poluzzi, E.2
Masetti, M.3
Cavalli, A.4
De Ponti, F.5
-
14
-
-
30344462409
-
Prolonged QTc interval and risk of sudden cardiac death in a population of older adults
-
Straus SM, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol. 2006;47:362-367.
-
(2006)
J Am Coll Cardiol.
, vol.47
, pp. 362-367
-
-
Straus, S.M.1
Kors, J.A.2
De Bruin, M.L.3
-
16
-
-
35348851892
-
The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients
-
Yavas O, Yazici M, Eren O, Oyan B. The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients. Swiss Med Wkly. 2007;137:556-558.
-
(2007)
Swiss Med Wkly.
, vol.137
, pp. 556-558
-
-
Yavas, O.1
Yazici, M.2
Eren, O.3
Oyan, B.4
-
17
-
-
77949808844
-
A simple approach discriminating cardio-safe drugs from toxic ones
-
Falah M, Nassar T, Rayan A. A simple approach discriminating cardio-safe drugs from toxic ones. Bioinformation. 2009;3:389-393.
-
(2009)
Bioinformation.
, vol.3
, pp. 389-393
-
-
Falah, M.1
Nassar, T.2
Rayan, A.3
-
18
-
-
77957830531
-
Electrocardiographic assessment for therapeutic proteins-scientific discussion
-
Rodriguez I, Erdman A, Padhi D, et al. Electrocardiographic assessment for therapeutic proteins-scientific discussion. Am Heart J. 2010;160:627-634.
-
(2010)
Am Heart J.
, vol.160
, pp. 627-634
-
-
Rodriguez, I.1
Erdman, A.2
Padhi, D.3
-
19
-
-
2442562493
-
Drugs, hERG and sudden death
-
Brown AM. Drugs, hERG and sudden death. Cell Calcium. 2004;35:543-547.
-
(2004)
Cell Calcium.
, vol.35
, pp. 543-547
-
-
Brown, A.M.1
-
20
-
-
44949175102
-
Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents
-
Sarapa N, Britto MR. Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents. Expert Opin Drug Saf. 2008;7:305-318.
-
(2008)
Expert Opin Drug Saf.
, vol.7
, pp. 305-318
-
-
Sarapa, N.1
Britto, M.R.2
-
21
-
-
1842605531
-
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
-
Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004;5:317-328.
-
(2004)
Cancer Cell.
, vol.5
, pp. 317-328
-
-
Franklin, M.C.1
Carey, K.D.2
Vajdos, F.F.3
Leahy, D.J.4
de Vos, A.M.5
Sliwkowski, M.X.6
-
22
-
-
33644600485
-
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab
-
Adams CW, Allison DE, Flagella K, et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother. 2006;55:717-727.
-
(2006)
Cancer Immunol Immunother.
, vol.55
, pp. 717-727
-
-
Adams, C.W.1
Allison, D.E.2
Flagella, K.3
-
23
-
-
84892489026
-
Presented at: American Association for Cancer Research 101st Annual Meeting; April 17-21, 2010
-
Washington,DC.Abstract 5607
-
Fields CT, Crocker LM, Sliwkowski MX, et al. Presented at: American Association for Cancer Research 101st Annual Meeting; April 17-21, 2010; Washington,DC.Abstract 5607.
-
-
-
Fields, C.T.1
Crocker, L.M.2
Sliwkowski, M.X.3
-
24
-
-
84892488879
-
Drugs that prolong the QT interval and/or induce torsades de pointes
-
Accessed February 15, 2012
-
Arizona Center for Education and Research on Therapeutics. Drugs that prolong the QT interval and/or induce torsades de pointes. http://www.azcert.org/medical-pros/drug-lists/ browse-drug-list.cfm. Accessed February 15, 2012.
-
Arizona Center for Education and Research on Therapeutics.
-
-
-
25
-
-
84980098899
-
The duration of systole in the electrocardiogram of normal subjects and of patients with heart disease
-
Fridericia LS. The duration of systole in the electrocardiogram of normal subjects and of patients with heart disease. Acta Medica Scandinavica. 1920;53:469-486.
-
(1920)
Acta Medica Scandinavica.
, vol.53
, pp. 469-486
-
-
Fridericia, L.S.1
-
26
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors
-
Therasse P, Arbuck SG, Eisenhaur EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
-
(2000)
J Natl Cancer Inst.
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhaur, E.A.3
-
27
-
-
84860307997
-
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab-DM1, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer
-
Gupta M, LoRusso PM, Wang B, et al. Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab-DM1, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. J Clin Pharmacol. 2012;52:691-703.
-
(2012)
J Clin Pharmacol.
, vol.52
, pp. 691-703
-
-
Gupta, M.1
LoRusso, P.M.2
Wang, B.3
-
28
-
-
78650516508
-
Comparison of QTc data analysis methods recommended by the ICH E14 guidance and exposureresponse analysis: case study of a thorough QT study of asenapine
-
Chapel S, Hutmacher MM, Bockbrader H, de Greef R, Lalonde RL. Comparison of QTc data analysis methods recommended by the ICH E14 guidance and exposureresponse analysis: case study of a thorough QT study of asenapine. Clin Pharmacol Ther. 2011;89:75-80.
-
(2011)
Clin Pharmacol Ther.
, vol.89
, pp. 75-80
-
-
Chapel, S.1
Hutmacher, M.M.2
Bockbrader, H.3
de Greef, R.4
Lalonde, R.L.5
-
29
-
-
37349079996
-
Concentration- QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review
-
Garnett CE, Beasley N, Bhattaram VA, et al. Concentration- QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol. 2008;48:13-18.
-
(2008)
J Clin Pharmacol.
, vol.48
, pp. 13-18
-
-
Garnett, C.E.1
Beasley, N.2
Bhattaram, V.A.3
-
31
-
-
84892488993
-
Pharmacokinetics (PK) of trastuzumab-DM1 (T-DM1) and paclitaxel in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with a trastuzumab-containing regimen
-
December 8-12, 2010; San Antonio, TX. Abstract P3-14-22
-
Lu D, Krop IE, Modi S, et al. Pharmacokinetics (PK) of trastuzumab-DM1 (T-DM1) and paclitaxel in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with a trastuzumab-containing regimen. Presented at: San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX. Abstract P3-14-22.
-
Presented at: San Antonio Breast Cancer Symposium
-
-
Lu, D.1
Krop, I.E.2
Modi, S.3
-
32
-
-
84865748679
-
Drug interaction potential of trastuzumab emtansine combined with pertuzumab in patients with HER2-positive metastatic breast cancer
-
Lu D, Burris HA III, Wang B, et al. Drug interaction potential of trastuzumab emtansine combined with pertuzumab in patients with HER2-positive metastatic breast cancer. Current Drug Metab. 2012;13:911-922.
-
(2012)
Current Drug Metab.
, vol.13
, pp. 911-922
-
-
Lu, D.1
Burris, H.A.2
Wang, B.3
-
33
-
-
23244455101
-
Population pharmacokinetics of trastuzumab in patients with HER2 metastatic breast cancer
-
Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P. Population pharmacokinetics of trastuzumab in patients with HER2 metastatic breast cancer. Cancer Chemother Pharmacol. 2005;56:361-369.
-
(2005)
Cancer Chemother Pharmacol.
, vol.56
, pp. 361-369
-
-
Bruno, R.1
Washington, C.B.2
Lu, J.F.3
Lieberman, G.4
Banken, L.5
Klein, P.6
-
34
-
-
84862228236
-
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2- positive cancer
-
Girish S, Gupta M, Wang B, et al. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2- positive cancer. Cancer Chemother Pharmacol. 2012;69: 1229-1240.
-
(2012)
Cancer Chemother Pharmacol.
, vol.69
, pp. 1229-1240
-
-
Girish, S.1
Gupta, M.2
Wang, B.3
-
35
-
-
64349093768
-
Assessing proarrhythmic potential of drugs when optimal studies are infeasible
-
836.e1,doi: 10.1016/j.ahj.2009.02.020
-
Rock EP, Finkle J, Fingert HJ, et al. Assessing proarrhythmic potential of drugs when optimal studies are infeasible. Am Heart J. 2009;157:827-836, 836.e1. doi: 10.1016/j.ahj.2009.02.020.
-
(2009)
Am Heart J.
, vol.157
, pp. 827-836
-
-
Rock, E.P.1
Finkle, J.2
Fingert, H.J.3
-
36
-
-
40249094483
-
Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development
-
Curigliano G, Spitaleri G, Fingert HJ, et al. Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development. Eur J Cancer. 2008;44:494-500.
-
(2008)
Eur J Cancer.
, vol.44
, pp. 494-500
-
-
Curigliano, G.1
Spitaleri, G.2
Fingert, H.J.3
-
37
-
-
84892489003
-
A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab for patients with HER2-positive, locally advanced or metastatic breast cancer: interim efficacy and safety results
-
Presented at: San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX. Abstract P3-14-01
-
Dieras V, Harbeck N, Albain K, et al. A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab for patients with HER2-positive, locally advanced or metastatic breast cancer: interim efficacy and safety results. Presented at: San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX. Abstract P3-14-01.
-
-
-
Dieras, V.1
Harbeck, N.2
Albain, K.3
|